Corporate Profile
Pliant Therapeutics is a clinical-stage biopharmaceutical company and leader in the discovery and development of novel integrin-based therapeutics. Pliant is conducting a Phase 1 study of PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors.
Stock Information
| (Common Stock) | |
|---|---|
| Exchange | |
| Price | |
| Change (%) | |
| Volume | |
Minimum 15 minutes delayed. Source: LSEG
Investor & Media Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications